×
About 262 results
Hirsutism in Women
https://www.aafp.org/afp/2019/0801/p168.html

Jul 31st, 2019 - Hirsutism is the excessive growth of terminal hair in a typical male pattern in a female. It is often a sign of excessive androgen levels. Although many conditions can lead to hirsutism, polycystic ovary syndrome and idiopathic hyperandrogenism account for more than 85% of cases. Less common causes include idiopathic hirsutism, nonclassic congenital adrenal hyperplasia, androgen-secreting tumor...

Don't Use Growth Hormone for Anti-Aging, Say New Guidelines
https://www.medscape.com/viewarticle/922195

Dec 4th, 2019 - The 2019 Guidelines for Management of Growth Hormone Deficiency in Adults and Patients Transitioning from Pediatric to Adult Care issued by two key US endocrine societies cover important developments in the decade since the previous version.   The full text, by Kevin C.J. Yuen, MD, and colleagues, is available online in Endocrine Practice.   Among other topics, the guidelines discuss currently ...

New insights, advances offer better perspective on AGHD
https://www.mdedge.com/clinicianreviews/article/200908/pituitary-thyroid-adrenal-disorders/new-insights-advances-offer?channel=206
Randy Dotinga

May 14th, 2019 - LOS ANGELES – Recent research, a new test, and upcoming guidelines are providing insight into the diagnosis of adult growth hormone deficiency and the importance of treatment, Kevin C. J.

DRESS Syndrome Induced by Telaprevir: A Potentially Fatal Adverse Event in Chronic Hepatitis C Therapy
https://www.mdedge.com/dermatology/article/189925/infectious-diseases/dress-syndrome-induced-telaprevir-potentially-fatal?channel=234
Pablo Fernández-Crehuet, MD, PhD, Ricardo Ruiz-Villaverde, MD, PhD

Nov 30th, 2018 - To the Editor: A 58-year-old woman with a history of hyperprolactinemia and gastrointestinal angiodysplasia presented to the dermatology department with a generalized skin rash of 3 weeks’ duration. She did not have a history of toxic habits.

Macimorelin for Diagnosis of Adult Growth Hormone Deficiency in EU
https://www.medscape.com/viewarticle/905314

Nov 18th, 2018 - The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has issued a positive opinion on an orally available ghrelin agonist macimorelin (Macimorelin, Aeterna Zentaris) to be used in the diagnosis of patients with adult growth hormone deficiency. Adult growth hormone deficiency is a rare disorder characterized by the inadequate secretion of growth hormone from ...

Copeptin Test Can Detect Diabetes Insipidus vs Other Polyuria
https://www.medscape.com/viewarticle/900473

Aug 8th, 2018 - A blood test for copeptin, a precursor of antidiuretic hormone (ADH, vasopressin), differentiates between "harmless" polydipsia-polyuria and diabetes insipidus more quickly and accurately than a traditional water-deprivation test, researchers report. Measuring plasma levels of copeptin after a 2-hour saline infusion was more accurate than being deprived of fluids for 16 hours. The latter is a t...

Copeptin Testing Tops Water-Deprivation for Diabetes Insipidus Dx
https://www.medpagetoday.com/primarycare/diabetes/74358

Aug 1st, 2018 - Action Points A diagnostic test involving direct detection of plasma copeptin using a hypertonic saline infusion was more accurate than the traditional indirect water-deprivation test for diagnosing diabetes insipidus, according to an international, multicenter, prospective study. Note that the test involving direct detection of plasma copeptin using a hypertonic saline infusion was better able...

Fast Five Quiz: Test Your Knowledge of Diabetes Insipidus
https://www.medscape.com/viewarticle/897260

May 29th, 2018 - Diabetes insipidus is defined as the passage of large volumes of dilute urine. It has two major forms: central and nephrogenic. Central diabetes insipidus is characterized by decreased secretion of antidiuretic hormone (ADH), which gives rise to polyuria and polydipsia by diminishing the person's ability to concentrate urine. Nephrogenic diabetes insipidus is characterized by a decrease in the ...

Prolactin, the pituitary, and pregnancy: Where’s the balance?
https://www.mdedge.com/endocrinology/article/164370/pituitary-thyroid-adrenal-disorders/prolactin-pituitary-and-pregnancy?channel=287
Kari Oakes

Apr 26th, 2018 - CHICAGO – Management of fertility and reproduction for women with prolactin-secreting pituitary tumors is a balancing act, often in the absence of robust data to support clinical decision making. So judgment, communication, and paying attention to the patient become paramount considerations, said endocrinologist Mark Molitch, MD, speaking at the annual meeting of the Endocrine Society.

Strategies for managing medication-induced hyperprolactinemia
https://www.mdedge.com/psychiatry/article/159114/schizophrenia-other-psychotic-disorders/strategies-managing-medication?channel=36771
Hilary Navy, PharmD, BCGP, Kristen Gardner, PharmD, BCPP

Mar 1st, 2018 - Ms. E, age 23, presents to your office for a routine visit for management of bipolar I disorder and posttraumatic stress disorder with comorbid type 2 diabetes mellitus.

Oral Test for Adult Growth Hormone Deficiency Approved in US
https://www.medscape.com/viewarticle/890457

Dec 20th, 2017 - The US Food and Drug Administration (FDA) has approved an orally available ghrelin agonist, macimorelin (Macrilen, Aeterna Zentaris), to be used in the diagnosis of patients with adult growth-hormone deficiency (AGHD). Macimorelin stimulates the secretion of growth hormone from the pituitary gland into the circulatory system. Stimulated growth-hormone levels are measured in four blood samples o...

Canada's Aeterna gets FDA approval for growth hormone deficiency test
https://www.reuters.com/article/us-aeterna-zentaris-fda/canadas-aeterna-gets-fda-approval-for-growth-hormone-deficiency-test-idUSKBN1EE2VQ

Dec 20th, 2017 - (Reuters) - Canada’s Aeterna Zentaris Inc said on Wednesday the U.S. Food and Drug Administration has approved its oral test to diagnose adult growth hormone deficiency. The company said it intends to launch the test, Macrilen, in the United States during the first quarter of 2018. Macrilen stimulates the secretion of growth hormone, which is then measured via blood samples. Aeterna said Macril...

Schizophrenia’s silent epidemic: Iatrogenic sexual dysfunction
https://www.mdedge.com/psychiatry/article/152504/schizophrenia-other-psychotic-disorders/schizophrenias-silent-epidemic
Bruce Jancin

Nov 20th, 2017 - PARIS – Many psychiatrists have no inkling of how often the antipsychotic agents they prescribe cause hyperprolactinemia-related sexual dysfunction, or the serious negative consequences these common side effects have on quality of life and treatment adherence, Ángel L. Montejo, MD, PhD, declared at the annual congress of the European College of Neuropsychopharmacology.

Versartis growth hormone drug fails key study, shares sink
https://www.reuters.com/article/us-versartis-study/versartis-growth-hormone-drug-fails-key-study-shares-sink-idUSKCN1BW31Q

Sep 21st, 2017 - (Reuters) - Versartis Inc said its experimental drug for the treatment of growth hormone deficiency in children did not meet the main goal of a late-stage study, sending its shares tanking 85 percent. The drug, somavaratan, is a long-acting recombinant human growth hormone. The company said patients receiving somavaratan failed to show non-inferiority, compared with patients on Pfizer Inc’s dru...

Gamma Knife Radiosurgery Safe in Early Pituitary Tumor
https://www.medscape.com/viewarticle/879250

Apr 27th, 2017 - LOS ANGELES — Treatment of residual nonfunctioning pituitary macroadenomas with Gamma Knife (Elekta) radiosurgery shows significantly greater benefit in reducing progression without an increase in endocrinopathies when used early after surgery compared with more than 6 months later in cases where clinicians opt for a "wait-and-watch" approach, according to new research. "We found a significantl...

Most children with growth disorders benefit from growth hormone
https://www.mdedge.com/pediatrics/article/135381/pediatrics/most-children-growth-disorders-benefit-growth-hormone?channel=206
Michele G. Sullivan

Apr 8th, 2017 - ORLANDO – About 80% of children with growth disorders will attain their expected normal adult height if adequately treated with growth hormone, a large observational study has determined. Somatropin recombinant human growth hormone seemed most effective for patients with growth hormone deficiency, idiopathic short stature, and for those who were born small for gestational age.

Growth hormone deficiency drug from OPKO and Pfizer fails study
https://www.reuters.com/article/us-opko-health-trial/growth-hormone-deficiency-drug-from-opko-and-pfizer-fails-study-idUSKBN14J1AX

Dec 30th, 2016 - (Reuters) - OPKO Health Inc said its experimental drug for growth hormone deficiency (GHD) in adults failed to provide a statistically significant benefit over a placebo in a late-stage study, sending its shares down about 17 percent on Friday. Miami-based OPKO, which is developing the drug, hGH-CTP, with Pfizer Inc, said on Friday it had identified one or more outliers that may have affected t...

Pituitary Hormones Should Be 'Restored to Healthy Levels'
https://www.medscape.com/viewarticle/870650

Oct 19th, 2016 - Patients with hypopituitarism should have their hormone levels restored as close to physiologic levels as possible, while taking into account potential interactions between hormones and other medications, say new guidelines on diagnosing and managing the syndrome. In its first clinical-practice guideline on the topic, the Endocrine Society states that the diagnosis and monitoring of the various...

Novel agent for adult GH can be administered once weekly
https://www.mdedge.com/familymedicine/article/105631/pituitary-thyroid-adrenal-disorders/novel-agent-adult-gh-can-be
Clinical Endocrinology News; Doug Brunk

Jan 7th, 2016 - Use of a novel reversible albumin-binding human growth hormone (GH) derivative administered subcutaneously once weekly for 4 weeks was safe and effective in adults with growth hormone deficiency, according to a phase I, randomized, open-label trial. Results from a recent clinical trial of the agent, known as NNC0195-0092 and being developed by Norvo Nordisk, indicated the feasibility of a once-.